A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs BMS 986016 (Primary) ; Nivolumab (Primary) ; Urelumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 29 Aug 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 29 Aug 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.
- 05 Feb 2016 New trial record